ARCHIVES

Also Von Eschenbach role in industry program raises new concerns of conflict of interest.

This article is from The Cancer Letter archive.

Vol. 31 No. 43 | November 23, 2005

Download PDF Visit The Full Archive

Related Articles

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

June 25, 2010

NTP Staff Members In Bethesda Told They Must Move

December 16, 1983

House May Add $80 Million To NCI Budget For FY 1984

September 16, 1983

Phase III Lung and Pancreatic Cancer Trials Are Stopped

April 30, 2010

Will Insurers Pay Patient Care Costs? Stay Tuned For Act II Of This Oncodrama

July 31, 1998

Genetic Testing: No Easy Answers To Public Questions

May 15, 1998